AI-assisted, human-published
02/24/2026 /Funding Events
Slate Medicines Secures $130 Million Series A Financing and Licenses Anti-Migraine Antibody
Slate Medicines has wrapped up a $130 million Series A financing round and obtained the rights to SLTE-1009, an anti-PACAP monoclonal antibody.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com